HBV Mutation Detail Information

> I169L Search Result


Mutation Information
Mutation Site I169L
Mutation Type Amino acid level
Gene/Protein/Region Type RT
Combined Mutation rt.M204V+rt.S202G+rt.I169L+rt.L180M
Relevant Drug lamivudine (LAM);entecavir (ETV)
Literature Information
PubMed PMID 17239478
Disease Chronic hepatitis B; Liver cirrhosis
Published Year 2007
Journal Journal of hepatology
Title Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Author Villet S,Ollivet A,Pichoud C,Barraud L,Villeneuve JP,Trépo C,Zoulim F
Evidence The triple mutant (rtL180M+S202G+M204V), which became the dominant strain at the end of entecavir and at the beginning of lamivudine+adefovir therapies, displayed with the rtI169L+L180M+S202G+M204V the highest resistance to entecavir (≈1300- and ≈1200-fold compared to wt HBV).

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation